Phenol Concentrations During Childhood and Subsequent Measures of Adiposity Among Young Girls

Insights

Childhood exposure to certain phenols may impact girls' adiposity. Enterolactone was linked to lower body fat, while 2,5-dichlorophenol was linked to higher body fat. Triclosan

Area of Science:

  • Environmental health
  • Endocrinology
  • Pediatric health

Background:

  • Phenolic compounds are environmental chemicals with potential endocrine-disrupting effects.
  • Childhood exposure to phenols from various sources is a growing concern.
  • Understanding the link between early-life exposures and long-term health outcomes is crucial.

Purpose of the Study:

  • To investigate longitudinal associations between childhood phenol exposure and adiposity measures in girls.
  • To examine specific phenol metabolites including enterolactone, genistein, and bisphenol A.
  • To assess changes in body mass index, waist circumference, and body fat percentage from childhood through adolescence.

Main Methods:

  • Longitudinal study of 1,017 girls from ages 6-8 to 15 years.
  • Measurement of urinary phenol metabolite concentrations at baseline.
  • Linear mixed-effects regression models to analyze associations between phenol exposure and adiposity.
  • Assessment of body mass index, waist circumference, and percent body fat.

Main Results:

  • Enterolactone exposure was inversely associated with all adiposity measures.
  • 2,5-dichlorophenol exposure was positively associated with all adiposity measures.
  • Triclosan showed a nonmonotonic association, positively linked to adiposity only in overweight girls.

Conclusions:

  • Childhood exposure to specific phenols influences adolescent adiposity.
  • Enterolactone and 2,5-dichlorophenol show opposing associations with body fat.
  • Early-life phenol exposure may be a modifiable factor in preventing childhood obesity.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387
Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.7K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Concentrations: Measurements01:23

Drug Concentrations: Measurements

Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
1.2K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
392